The US Department of Justice issued subpoenas to two makers of generic pharmaceuticals last week, sparking an investigation into the industry and its competition. Now, report say, the case is already growing.
Generic drug makers Lannett and Impax Laboratories both confirmed they were contacted by the DOJ as part of a probe into their relationships with rivals. Impax added that the subpoena demanded one of its sales representatives to hand over documents and offer testimony about communication with rival drug makers.
The DOJ also revealed details of its investigation in a filing with the Securities and Exchange Commission.
Reports released earlier this year found that the price of some generic drugs charged to pharmacies has nearly doubled in the last year – leading prices for consumers to, in some cases, triple.
Connecticut’s Attorney General launched an investigation earlier this year into price hikes for congestive heart failure drug digoxin, a drug made by both Lannett and Impax, say reports.
Full content: Wall Street Journal
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
Featured News
Redfin Settles $9.2M Commission Inflation Lawsuits
May 7, 2024 by
CPI
DOJ Supports Colorado’s Efforts to Block Kroger-Albertsons Merger
May 7, 2024 by
CPI
Japan Considers Regulation of AI Developers
May 7, 2024 by
CPI
European Commission Extends Decision Deadline for Ita-Lufthansa Merger
May 7, 2024 by
CPI
UK, US and Australia Sanction Senior Leader of LockBit Cybercrime Gang
May 7, 2024 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Economics of Criminal Antitrust
Apr 19, 2024 by
CPI
Navigating Economic Expert Work in Criminal Antitrust Litigation
Apr 19, 2024 by
CPI
The Increased Importance of Economics in Cartel Cases
Apr 19, 2024 by
CPI
A Law and Economics Analysis of the Antitrust Treatment of Physician Collective Price Agreements
Apr 19, 2024 by
CPI
Information Exchange In Criminal Antitrust Cases: How Economic Testimony Can Tip The Scales
Apr 19, 2024 by
CPI